In patients with MDS or MDS/MPN, recurrent loss-of-function EZH2 mutations [6–8] are associated with a poor prognosis [9], and EZH2 is considered by many to act as a bona fide tumor suppressor gene [10, 11]. The gene discussed is EZH2; the disease is myeloproliferative neoplasm.